You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

BCMA-Directed Therapy in Multiple Myeloma: Assessing the Clinical Impact

  • Authors: Nikhil Munshi, MD; Nina Shah, MD; Saad Usmani, MD, MBA, FACP
  • CME / ABIM MOC Released: 2/18/2022
  • Valid for credit through: 2/18/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for community-based hematologists/oncologists and others engaged in the care of patients with multiple myeloma (MM).

The goal of this activity is to improve the knowledge of clinicians about the rationale for targeting B-cell maturation antigen (BCMA) in myeloma, the impact of current BCMA-directed therapies, toxicity management, and emerging agents.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of BCMA-directed therapies in the MM treatment paradigm
    • Emerging BCMA-targeted therapeutic approaches for MM
  • Have greater competence related to
    • Managing toxicities of available BCMA-directed therapies
  • Demonstrate greater confidence in their ability to
    • Integrate BCMA-directed therapies into clinical practice


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Nikhil Munshi, MD

    Kraft Family Chair and Professor of Medicine
    Dana Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    Advisor or consultant for: Amgen; Bristol Myers Squibb; GlaxoSmithKline; Jannsen; Karyopharm; Ledgend; Novartis; Oncopep; Pfizer
    Royalties or patent beneficiary: Oncopep
    Stocks, stock options, or bonds from: C4 Therapeutics
    Ownership of an ineligible company: Oncopep

  • Nina Shah, MD

    Professor of Clinical Medicine
    Division of Hematology/Oncology
    University of California San Francisco
    San Francisco, California

    Disclosures

    Grants for clinical research from: Bluebird Bio; Celgene/Bristol Myers Squibb; Janssen; Nektar; Poseida; Precision Biosciences; Sutro Biopharma; Teneobio
    Advisor or consultant for: Amgen; CareDx; CSL Behring; GlaxoSmithKline; Indapta Therapeutics; Karyopharm; Kite; Oncopeptides; Sanofi

  • Saad Usmani, MD, MBA, FACP

    Chief of Myeloma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Grants for clinical research from: Amgen; Array Biopharma; Bristol Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Merck; Pharmacyclics; Sanofi; Seagen Inc., formerly Seattle Genetics., Inc.; SkylineDX; Takeda 
    Advisor or consultant for: Abbvie; Amgen; Bristol Myers Squibb; Celgene; EdoPharma; Gilead; Genentech; GlaxoSmithKline; Janssen; Oncopeptides; Sanofi; Seagen Inc., formerly Seattle Genetics Inc.; SecuraBio; SkylineDX; Takeda; TeneoBio 
    Speaker or member of speakers bureau for: Amgen; Bristol Myers Squibb; Janssen; Sanofi 

Editor

  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC  

    Disclosures

    Disclosure: Megan Whitney, DMD, has disclosed no relevant financial relationships

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

BCMA-Directed Therapy in Multiple Myeloma: Assessing the Clinical Impact

Authors: Nikhil Munshi, MD; Nina Shah, MD; Saad Usmani, MD, MBA, FACPFaculty and Disclosures

CME / ABIM MOC Released: 2/18/2022

Valid for credit through: 2/18/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

The Role of BCMA in Multiple Myeloma

Dr Mushi provides an overview of BCMA biology.
Nikhil Munshi, MD

Targeting BCMA in Myeloma Therapy

Dr Munshi discusses the mechanisms of BCMA-directed therapy.
Nikhil Munshi, MD

Antibody-Drug Conjugates

Dr Shah provides trial evidence and clinical context for the use of BCMA-directed antibody-drug conjugates.
Nina Shah, MD

CAR T-Cell Therapy

Dr Usmani reviews key updates on new and emerging CAR T-cell therapies.
Saad Usmani, MD, MBA, FACP

Bispecific Antibodies

Dr Shah reviews the latest data on bispecific antibodies and provides clinical pearls for selecting BCMA-directed therapies for myeloma.
Nina Shah, MD
 

Educational Impact Challenge

The goal of this activity is to improve the knowledge of clinicians about the rationale for targeting B-cell maturation antigen (BCMA) in myeloma, the impact of current BCMA-directed therapies, toxicity management, and emerging agents.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print